← Asustek Computer overview

Asustek Computer vs Globus Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Asustek Computer Inc (2357.TW)

Q3 2026
▲3▼1

ASUS beats on Q2 earnings, pivots hard into AI hardware

  • PC demand softens on higher component costs Global PC shipments fell 3.6% year-on-year in Q2 2026 as memory and storage costs pushed prices up 20-40%, and about 60% of channel partners said customers were delaying or cancelling refreshes. That weakens ASUS's core PC business, a drag on the stock.

    Shows the demand headwind hitting ASUS's main business, the counterweight to the AI story.

  • Q2 earnings beat with 38.5% revenue growth ASUS reported Q2 GAAP EPS of NT$25.60 on revenue of NT$241.06 billion, up 38.5% from a year earlier, and gave a third-quarter outlook. Strong profit growth reassures investors that the business is expanding despite weak PC unit demand.

    The single biggest company-specific fact this period, directly moving the stock.

  • AI optimism lifts peers and ASUS shares Lenovo shares jumped 22% on a big revenue beat, with analysts calling AI-driven growth structural. ASUS rose 10% the same day after reporting a 61% increase in first-half operating profit, showing investors are re-rating PC makers as AI plays.

    Explains the market mood and money flowing into the sector that lifted ASUS's price.

  • ASUS pushes into AI PCs, servers and AI factories At IFA and AI Tech 2026, ASUS launched ProArt laptops with NVIDIA RTX Spark for local AI, plus servers and edge computers with Intel, AMD and NVIDIA, and a unified AI factory platform. This opens new, higher-margin revenue beyond PCs.

    Shows the new growth engine investors are pricing in, the main reason for optimism.

August 2026
▲3▼1

ASUS beats on Q2 earnings, pivots hard into AI hardware

  • PC demand softens on higher component costs Global PC shipments fell 3.6% year-on-year in Q2 2026 as memory and storage costs pushed prices up 20-40%, and about 60% of channel partners said customers were delaying or cancelling refreshes. That weakens ASUS's core PC business, a drag on the stock.

    Shows the demand headwind hitting ASUS's main business, the counterweight to the AI story.

  • Q2 earnings beat with 38.5% revenue growth ASUS reported Q2 GAAP EPS of NT$25.60 on revenue of NT$241.06 billion, up 38.5% from a year earlier, and gave a third-quarter outlook. Strong profit growth reassures investors that the business is expanding despite weak PC unit demand.

    The single biggest company-specific fact this period, directly moving the stock.

  • AI optimism lifts peers and ASUS shares Lenovo shares jumped 22% on a big revenue beat, with analysts calling AI-driven growth structural. ASUS rose 10% the same day after reporting a 61% increase in first-half operating profit, showing investors are re-rating PC makers as AI plays.

    Explains the market mood and money flowing into the sector that lifted ASUS's price.

  • ASUS pushes into AI PCs, servers and AI factories At IFA and AI Tech 2026, ASUS launched ProArt laptops with NVIDIA RTX Spark for local AI, plus servers and edge computers with Intel, AMD and NVIDIA, and a unified AI factory platform. This opens new, higher-margin revenue beyond PCs.

    Shows the new growth engine investors are pricing in, the main reason for optimism.

Latest
▲3▼1

ASUS beats on Q2 earnings, pivots hard into AI hardware

  • PC demand softens on higher component costs Global PC shipments fell 3.6% year-on-year in Q2 2026 as memory and storage costs pushed prices up 20-40%, and about 60% of channel partners said customers were delaying or cancelling refreshes. That weakens ASUS's core PC business, a drag on the stock.

    Shows the demand headwind hitting ASUS's main business, the counterweight to the AI story.

  • Q2 earnings beat with 38.5% revenue growth ASUS reported Q2 GAAP EPS of NT$25.60 on revenue of NT$241.06 billion, up 38.5% from a year earlier, and gave a third-quarter outlook. Strong profit growth reassures investors that the business is expanding despite weak PC unit demand.

    The single biggest company-specific fact this period, directly moving the stock.

  • AI optimism lifts peers and ASUS shares Lenovo shares jumped 22% on a big revenue beat, with analysts calling AI-driven growth structural. ASUS rose 10% the same day after reporting a 61% increase in first-half operating profit, showing investors are re-rating PC makers as AI plays.

    Explains the market mood and money flowing into the sector that lifted ASUS's price.

  • ASUS pushes into AI PCs, servers and AI factories At IFA and AI Tech 2026, ASUS launched ProArt laptops with NVIDIA RTX Spark for local AI, plus servers and edge computers with Intel, AMD and NVIDIA, and a unified AI factory platform. This opens new, higher-margin revenue beyond PCs.

    Shows the new growth engine investors are pricing in, the main reason for optimism.

Globus Medical (GMED)

Q3 2026
▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

  • Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.

    The latest earnings beat and guidance raise are the clearest new evidence of business strength.

  • AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.

    A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.

  • EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.

    New regulatory clearance opens European commercialization, a concrete new growth avenue.

  • Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.

    These are the main new negatives: a sector demand scare and a legal/governance investigation.

August 2026
▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

  • Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.

    The latest earnings beat and guidance raise are the clearest new evidence of business strength.

  • AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.

    A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.

  • EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.

    New regulatory clearance opens European commercialization, a concrete new growth avenue.

  • Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.

    These are the main new negatives: a sector demand scare and a legal/governance investigation.

Latest
▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

  • Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.

    The latest earnings beat and guidance raise are the clearest new evidence of business strength.

  • AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.

    A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.

  • EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.

    New regulatory clearance opens European commercialization, a concrete new growth avenue.

  • Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.

    These are the main new negatives: a sector demand scare and a legal/governance investigation.